<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82756">
  <stage>Registered</stage>
  <submitdate>23/04/2008</submitdate>
  <approvaldate>30/04/2008</approvaldate>
  <actrnumber>ACTRN12608000224325</actrnumber>
  <trial_identification>
    <studytitle>Australian BioEnterics Intragastric Balloon (BIB) study in obese subjects with metabolic syndrome</studytitle>
    <scientifictitle>A prospective, randomised, open-label, controlled study of safety and efficacy of the BioEnterics Intragastric Balloon (BIB) system in the treatment of obese participants with metabolic syndrome, with or without other obesity-related co-morbidities</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obesity and associated metabolic syndrome, with or without other obesity-related co-morbidities</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Non-surgical intervention with intragastric balloon inserted into the stomach under endoscopic visualisation for a total of 6 months, as an adjunct to a 12 month behavioural management programme of supervised diet and exercise (A balanced diet high in whole grains, fruit and vegetables and with reduced fat intake. A moderate exercise regimen of at least 30 minutes/day will be instituted. This programme will be individualised and assessed each month by the study dietitian and the study exercise physiologist and will be amended as required)</interventions>
    <comparator>12 month behavioural management programme (supervised diet &amp; exercise)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relative % weight reduction from baseline for the two treatment groups</outcome>
      <timepoint>Month 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>% with a resolution of metabolic syndrome (defined as &lt; 3 criteria from the 3rd Report of the National Cholesterol Education Program's Adult Treatment Panel [ATP III], which defines metabolic syndrome on the basis of fasting plasma glucose &amp; triglyceride levels; waist circumference; HDL-cholesterol levels &amp; blood pressure)</outcome>
      <timepoint>Months 0, 3, 6, 9 &amp; 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>% achieving a reduction in body weight of &gt; 10%</outcome>
      <timepoint>Months 0, 3, 6, 9 &amp; 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>% with improvement or resolution of other obesity-related co-morbidities (including systemic hypertension; type 2 diabetes; &amp; dyslipidaemia, which will be defined by improvement or normalisation of blood pressure, with reduction or discontinuation of antihypertensives; improvement or normalisation of biochemical markers with with reduction or discontinuation of anti-diabetic agents and improvement or normalisation of biochemical markers, respectively</outcome>
      <timepoint>Months 0, 3, 6, 9 &amp; 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in exercise tolerance (6 minute walk test)</outcome>
      <timepoint>Months 0, 3, 6, 9 &amp; 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in quality of life/health status (Impact of Weight on Quality of Life [IWQOL] Questionnaire, Assessment of Quality of Life [AQOL] Questionnaire, Beck Depression Inventory [BDI])</outcome>
      <timepoint>Months 0, 3, 6, 9 &amp; 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(i) Body Mass Index (BMI) between 30 &amp; 40 kg/m2 with metabolic syndrome (ii) Failed attempts to lose weight with supervised weight loss programmes</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Specific  Gastrointenstinal [GI] diseases/conditions (e.g. inflammatory; bleeding; dysmotility) 
Prior gastric surgery; type 1 diabetes; untreated thyroid disease, hepatic or moderate to severe renal insufficiency; pregnancy; alcohol or drug dependence; psychiatric disorders; medication affecting weight or appetite</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>22/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan Australia</primarysponsorname>
    <primarysponsoraddress>810 Pacific Highway, Level 4, Gordon NSW 2072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Allergan Australia</fundingname>
      <fundingaddress>77 Ridge Street,
Gordon NSW 2072</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Halstead</name>
      <address>810 Pacific Highway, Level 4, Gordon NSW 2072</address>
      <phone>+61 2 9498-0167</phone>
      <fax>+61 2 9498-0184</fax>
      <email>halstead_michael@allergan.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nick Fuller</name>
      <address>Metabolism &amp; Obesity Research
Level 12, Page Building (14)
Royal Prince Alfred Hospital (RPAH)
Missenden Road. Camperdown NSW 2050</address>
      <phone>+61 2 9515 3685</phone>
      <fax />
      <email>nick.fuller@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Halstead</name>
      <address>810 Pacific Highway, Level 4, Gordon NSW 2072</address>
      <phone>+61 2 9498-0167</phone>
      <fax>+61 2 9498-0184</fax>
      <email>halstead_michael@allergan.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>